SEMINARS IN RADIATION ONCOLOGY is a premier journal published by W B SAUNDERS CO-ELSEVIER INC, dedicated to advancing the field of radiation oncology through high-quality research and comprehensive reviews. With an impressive impact factor and a notable HIndex, this journal holds a prominent place within the academic community, particularly illustrated by its Q2 ranking in both Cancer Research and Oncology, and a Q1 ranking in Radiology, Nuclear Medicine, and Imaging as of 2023. Since its inception in 1991, the journal has served as a vital resource for researchers, clinicians, and healthcare professionals, facilitating the exchange of innovative ideas and practices that shape the future of cancer treatment. While the journal is not open access, it offers essential insights into the latest advancements in the field, catering to a diverse audience eager to expand their knowledge and improve patient outcomes in the realm of radiation therapy.

Frontiers in Neurology is a premier open-access journal dedicated to the advancement of research in the field of neurology, published by FRONTIERS MEDIA SA since 2010. With the ISSN 1664-2295 and an international reach established from its base in Lausanne, Switzerland, this journal has rapidly become a vital resource for neurologists and neuroscientists alike, presenting high-quality research that addresses critical developments in clinical and experimental neurology. Holding a solid Q2 quartile ranking in both neurology and clinical neurology, Frontiers in Neurology demonstrates substantial influence, evidenced by its respectable Scopus rankings—151st in clinical neurology and 77th in neuroscience neurology. The journal employs robust peer review practices to ensure rigor and integrity, while its open-access model fosters widespread dissemination of knowledge. By facilitating interdisciplinary dialogue and empowering research efforts, this journal not only supports the academic community but also contributes to the advancement of treatment and understanding of neurological disorders.

Journal of Personalized Medicine is a pioneering open-access journal published by MDPI, renowned for its commitment to advancing research in the dynamic field of personalized healthcare. Since its inception in 2011, this journal has served as a critical platform for scholars, practitioners, and students interested in the integration of individualized therapies and diagnostic techniques that aim to tailor medical treatments to the unique characteristics of each patient. With an impressive Q2 ranking in the field of medicine, as recognized by Scopus, and currently holding a percentile rank of 65th, it stands out among its peers with a focus on innovative approaches that challenge traditional paradigms. Researchers can benefit from its open-access model, allowing for broader dissemination of findings that can significantly impact clinical practices and research directions globally. Set against the picturesque backdrop of Basel, Switzerland, the journal is positioned at the forefront of medical innovation, producing high-quality, peer-reviewed articles that span the latest advancements and applications in personalized medicine.

Discovery Medicine, an esteemed journal published by Discovery Medicine, serves as a vital platform within the field of general medicine, dedicated to advancing knowledge through high-quality research and innovative insights. With its ISSN 1539-6509 and E-ISSN 1944-7930, this journal boasts an impressive Scopus ranking of #29 out of 529 in the general medicine category, positioning it at the 94th percentile, indicating its significant contribution to the medical sciences. While operating as a subscription-based journal, Discovery Medicine fosters an environment where researchers and professionals can disseminate their findings and engage with cutting-edge developments in medicine. Spanning topics that bridge clinical practice and healthcare advancements, this journal aims to inform, challenge, and inspire the medical community. The journal has converged its volumes from 2006 to 2007 and again from 2009 to 2018, highlighting its sustained commitment to excellence even as coverage has temporarily discontinued in Scopus. Situated at 10 Gerard Ave, Ste 201, Timonium, MD 21093, Discovery Medicine continues to be a cornerstone for medical scholars, offering a rich repository of knowledge essential for ongoing research and practical applications.

GENETICS, published by the Genetics Society of America, stands as a preeminent journal in the field of genetics, with a keen focus on advancing the understanding of genetic principles and their implications across various biological systems. Since its inception in 1945, the journal has played a pivotal role in disseminating groundbreaking research, maintaining a Q1 ranking in the genetics category as of 2023, positioning it among the top tier of academic publications. While access to the journal is not open, it continues to attract a global readership of researchers, professionals, and students eager to engage with high-quality, peer-reviewed articles that span both classical and contemporary genetics. With its publication history covering critical decades from 1945 to 2024, GENETICS is not just a repository of scientific knowledge but a vibrant forum for the exchange of ideas that drive the field forward. The journal’s commitment to excellence is demonstrated by its strategic coverage of pertinent topics, assuring its relevance for future generations of scholars.

Welcome to the JOURNAL OF ORAL PATHOLOGY & MEDICINE, a distinguished publication dedicated to advancing knowledge within the realms of oral pathology and medicine. Published by WILEY since 1972, this journal has established itself as a critical resource for researchers and practitioners alike, covering a broad spectrum of topics related to oral health and disease. With an impressive array of rankings, including Q1 status in categories such as Oral Surgery and Periodontics, and a prominent position in Otorhinolaryngology, the journal is recognized for its substantial contributions to these fields. Although currently not open access, it remains pivotal in disseminating vital research findings, fostering collaboration and innovation among healthcare professionals. The interdisciplinary scope of the journal also supports its high impact factor and robust Scopus rankings, including a 92nd percentile in Otorhinolaryngology. By providing a platform for original research and reviews, the JOURNAL OF ORAL PATHOLOGY & MEDICINE plays an essential role in shaping future advancements in oral health sciences.

ONCOLOGIST is a premier, open-access journal published by Oxford University Press, advancing the field of cancer research since its inception in 1996. With an impressive H-Index and a prestigious placement within the Q1 category in Cancer Research, Medicine, and Oncology for 2023, ONCOLOGIST stands at the forefront of oncological science, boasting a Scopus rank of #55 out of 404 in Medicine and #47 out of 230 in Cancer Research. This journal not only disseminates cutting-edge research but also aims to foster multidisciplinary approaches that are critical for addressing the complex challenges faced in cancer therapy and survivorship. Be part of a vibrant community as you explore impactful research articles that contribute to the global conversation on cancer. ONCOLOGIST is dedicated to providing an accessible platform for authors and readers alike, ensuring that high-quality research is available to all stakeholders in the fight against cancer.

JCO Precision Oncology, published by Lippincott Williams & Wilkins, is a leading journal in the field of cancer research and oncology, recognized for its high-impact contributions and innovative approaches to precision medicine. Since its inception in 2017, this journal has consistently ranked in the Q1 category in both Cancer Research and Oncology for 2023, reflecting its esteemed position within the academic community. With a rigorous peer-review process and a focus on disseminating cutting-edge research, JCO Precision Oncology serves as a vital platform for researchers, clinicians, and healthcare professionals aiming to enhance the understanding and treatment of cancer through individualized therapies. The journal's comprehensive scope includes studies on genetic profiling, biomarker research, and novel therapeutic strategies, making it an essential resource for anyone involved in cancer care and research. Explore further and join a community committed to advancing precision oncology and improving patient outcomes.

Genome Medicine is a prestigious, peer-reviewed journal published by BMC, focusing on the rapidly evolving fields of genetics, molecular biology, and molecular medicine. Established in 2009 and boasting an open-access format, it has become a leading platform for disseminating high-quality research findings that advance our understanding of genetic diseases and therapeutic innovations. With an impressive Q1 ranking across multiple relevant categories—in particular, genetics (clinical), molecular biology, and molecular medicine—this journal is recognized for its substantial impact in the academic community, as evidenced by its exceptional placement in Scopus rankings. By providing unrestricted access to groundbreaking studies, Genome Medicine fosters collaboration and knowledge sharing among researchers, clinicians, and educators, thus playing a vital role in the transition from fundamental genetic research to clinical applications. Researchers are encouraged to contribute their findings and insights, further solidifying the journal’s position as a pivotal resource for those dedicated to advancing genomic medicine.

Expert Review of Precision Medicine and Drug Development, published by Taylor & Francis Ltd, is a valuable academic resource that thrives at the intersection of pharmacology, genetics, and molecular medicine. Since its inception in 2016, this journal has rapidly become a pivotal platform for researchers and practitioners aiming to advance the field of drug development through innovative precision medicine strategies. With a broad focus encompassing the latest advancements in drug discovery and genetic research, it operates within a competitive landscape, evidenced by its recent category quartile rankings where it holds Q4 in Drug Discovery, Genetics, and Molecular Medicine, alongside a Q3 ranking in Pharmacology for the year 2023. The journal offers a unique opportunity for scholars to share insights and foster collaborations that can lead to breakthroughs in therapeutic approaches. Although not an open-access journal, it maintains a commitment to disseminating outstanding research to a wide audience. By fostering a rigorous peer-review process, the journal aims to enhance the quality and impact of publications within these critical areas of medicine, making it an essential read for anyone involved in healthcare and pharmaceutical advancements.